Abstract
Iron-binding strategies in anticancer drug design target the key role of iron in cancer growth. The incorporation of a quinoline moiety in the design of tetrazolium-based prochelators facilitates their intracellular reduction/activation to iron-binding formazans. The new prochelators are antiproliferative at submicromolar levels, induce apoptosis and cell cycle arrest, and impact iron signaling in cancer cells.
MeSH terms
-
Antineoplastic Agents* / chemical synthesis
-
Antineoplastic Agents* / chemistry
-
Antineoplastic Agents* / pharmacology
-
Apoptosis* / drug effects
-
Cell Cycle Checkpoints / drug effects
-
Cell Line, Tumor
-
Cell Proliferation* / drug effects
-
Drug Screening Assays, Antitumor
-
Humans
-
Iron* / chemistry
-
Iron* / metabolism
-
Molecular Structure
-
Quinolines* / chemistry
-
Quinolines* / pharmacology
Substances
-
Quinolines
-
Antineoplastic Agents
-
Iron
-
quinoline